[3-(5-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-phenyl]-methanol | 540751-49-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: [3-(5-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-phenyl]-methanol
• 英文别名: [3-[5-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl]phenyl]methanol
• CAS: 540751-49-3
• 化学式: C₁₆H₁₃N₅O₂
• 分子量: 307.312
• InChiKey: PZEWPXMEDKMEQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [3-(5-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-phenyl]-methanol 在 氯化亚砜 、 potassium carbonate 、 三乙胺 、 potassium iodide 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 2-Furan-2-yl-7-(3-{4-[4-(2-methoxy-ethoxy)-phenyl]-piperazin-1-ylmethyl}-phenyl)-[1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine
  参考文献：
  名称：

  2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: Highly potent, orally active, adenosine A2A antagonists. Part 1

  摘要：

  The structure-activity relationship of this novel class of compounds based on 2-(2-furanyl)-7-phenyl[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine, 1, and its analogs was evaluated for their in vitro and in vivo adenosine A(2A) receptor antagonism. Several compounds displayed oral activity at 3 mg/kg in a rat catalepsy model. Specifically, compound 8g displayed an excellent in vitro profile, as well as a highly promising in vivo profile. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.086
• 作为产物：
  描述：

  3-羟甲基苯硼酸 在 四(三苯基膦)钯 、 N,O-双三甲硅基乙酰胺 、 potassium carbonate 作用下， 以 乙腈 、 正丁醇 为溶剂， 生成 [3-(5-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-phenyl]-methanol
  参考文献：
  名称：

  2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: Highly potent, orally active, adenosine A2A antagonists. Part 1

  摘要：

  The structure-activity relationship of this novel class of compounds based on 2-(2-furanyl)-7-phenyl[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine, 1, and its analogs was evaluated for their in vitro and in vivo adenosine A(2A) receptor antagonism. Several compounds displayed oral activity at 3 mg/kg in a rat catalepsy model. Specifically, compound 8g displayed an excellent in vitro profile, as well as a highly promising in vivo profile. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.086

文献信息

• Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
  申请人：Schering Corporation

  公开号：EP2269596A2

  公开（公告）日：2011-01-05

  There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS.

  本发明公开了一种治疗或预防锥体外系综合征（EPS）、肌张力障碍、不安腿综合征（RLS）或睡眠中周期性腿部运动（PLMS）的方法，该方法包括单独或与其他用于治疗EPS、肌张力障碍、RLS或PLMS的药物联合使用腺苷A2a受体拮抗剂。
• Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders
  申请人：Schering Corporation

  公开号：EP2295047A2

  公开（公告）日：2011-03-16

  There is disclosed a method for the treatment or prevention of restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating RLS or PLMS.

  本发明公开了一种治疗或预防不宁腿综合征（RLS）或睡眠中周期性腿部运动（PLMS）的方法，该方法包括单独使用腺苷 A2a 受体拮抗剂或与其他治疗 RLS 或 PLMS 的药物联合使用。
• Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
  申请人：Schering Corporation

  公开号：US20040138235A1

  公开（公告）日：2004-07-15

  There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS.

  本发明公开了一种治疗或预防锥体外系综合征（EPS）、肌张力障碍、不安腿综合征（RLS）或睡眠中周期性腿部运动（PLMS）的方法，该方法包括单独或与其他用于治疗EPS、肌张力障碍、RLS或PLMS的药物联合使用腺苷A2a受体拮抗剂。
• ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS
  申请人：Grzelak Michael

  公开号：US20090029967A1

  公开（公告）日：2009-01-29

  There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS.
• US7414058B2
  申请人：——

  公开号：US7414058B2

  公开（公告）日：2008-08-19